Biomarkers for Post-Transplant Lymphoproliferative Disorders in Children

CompletedOBSERVATIONAL
Enrollment

944

Participants

Timeline

Start Date

August 14, 2014

Primary Completion Date

May 15, 2019

Study Completion Date

May 15, 2019

Conditions
Heart TransplantSmall Intestine TransplantKidney TransplantLiver TransplantEBV-Related PTLDPTLDs
Interventions
PROCEDURE

transplant

All subjects enrolled in this study are candidates for/recipients of solid organ transplants as a therapeutic for end stage diseases (e.g., heart, liver, heart with liver, kidney, small intestine, or liver with small intestine transplants).

DRUG

Immunosuppressive Drugs

Immunosuppressive drugs prescribed as standard of care to prevent rejection of the allograft.

Trial Locations (7)

15224

Children's Hospital of Pittsburgh of UPMC, Pittsburgh

20057

Medstar Georgetown Transplant Institute, Washington D.C.

33101

University of Miami Health System, Miami

45229

Cincinnati Children's Hospital Medical Center, Cincinnati

75235

University of Texas Southwestern, Dallas

90095

University of California, Los Angeles, Los Angeles

94305

Lucile Packard Children's Hospital Stanford, Stanford

All Listed Sponsors
collaborator

Clinical Trials in Organ Transplantation in Children

OTHER

lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT02182986 - Biomarkers for Post-Transplant Lymphoproliferative Disorders in Children | Biotech Hunter | Biotech Hunter